1 week Ago By ABMN Staff
Valneva SE ( NASDAQ:VALN – Free Report ) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research report issued on Thursday, January 23rd. HC Wainwright analyst E. White forecasts that the company will earn ($0.
38) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock.
The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s Q2 2025 earnings at ($0.
29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.
Valneva Stock Up 3.4 % Shares of NASDAQ VALN opened at $4.90 on Friday.
Valneva has a 12 month low of $3.62 and a 12 month high of $9.50.
The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.
70. The firm has a market capitalization of $398.17 million, a price-to-earnings ratio of -37.
69 and a beta of 1.93. The business has a 50-day moving average of $4.
29 and a 200-day moving average of $5.78. Institutional Inflows and Outflows Valneva Company Profile ( Get Free Report ) Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. Further Reading Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter .
.
